Perrigo | PRGO - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Abbott USD 6.54B 625M 2025-12
Bayer EUR 5.35B 1.02B 2025-09
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Coherus Biosciences USD 8.7M 853K 2025-12
Corcept Therapeutics USD 199.58M 3.46M 2025-12
Dr.Reddys Laboratories INR 51.37B 629M 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
J&J USD 16.6B 118M 2025-12
Merck USD 13.42B 431M 2025-09
Nestle CHF 21.43B 174M 2024-12
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 157.37M 5.79M 2025-12
Reckitt Benckiser GBP 4.25B 2.08B 2024-12
Sanofi EUR 8.45B 1.31B 2025-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Teva Pharmaceutical Industries USD 2.66B 351M 2025-12
Xeris Pharmaceuticals USD 72.15M 8.77M 2025-12
Zoetis USD 1.64B 73M 2025-12